EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Clinical Course and Risk Factors of Lenvatinib‐Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study

Chihiro Shiraishi iD, Hideo Kato iD, Yuki Asai iD, Takuya Iwamoto iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70461 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Reports, 2026. Verfasst von Chihiro Shiraishi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Hypothyroidism, Liver Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenvatinib‐related hypothyroidism occurs in 16%–22% of patients with hepatocellular carcinoma and may affect treatment management. Previous studies have reported elevated serum thyroid stimulating hormone (TSH) levels despite levothyroxine therapy, indicating the need for research on the optimal levothyroxine dose during lenvatinib therapy.

Aims

We aimed to explore the effect of lenvatinib on thyroid function, focusing on lenvatinib pharmacokinetics and factors influencing hypothyroidism development. Methods and Results A retrospective cohort study involving 56 patients with hepatocellular carcinoma treated with lenvatinib was conducted at the Mie University Hospital. The primary outcome was grade ≥ 2 hypothyroidism. Demographic data, treatment details, and clinical outcomes were analyzed to identify factors associated with lenvatinib‐related hypothyroidism. In addition, we assessed the levothyroxine dose administered during treatment and the dose required to achieve TSH levels < 10 mIU/L. Twelve patients (21%) developed hypothyroidism during lenvatinib therapy. The median levothyroxine dose and time to onset of hypothyroidism were 25.0 [25.0–50.0] μg/day and 81.0 [15.0–208.0] days, respectively. Levothyroxine therapy was initiated at either a low or recommended dose, with 10 patients achieving TSH levels < 10 mIU/L. Significant predictors of hypothyroidism included age ≤ 63 years and a higher daily lenvatinib dose (≥ 0.152 mg/kg/day).

Conclusion

Initiation of levothyroxine therapy, even at lower doses, may be effective in managing lenvatinib‐related hypothyroidism. Underweight patients (e.g., body weight < 50 kg) require particular attention due to their increased susceptibility to hypothyroidism. Even though this study has limitations such as a small sample size and the lack of multivariate analysis, it provides valuable information for managing lenvatinib‐related hypothyroidism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsQuinolinesHypothyroidismLiver NeoplasmsCarcinoma, HepatocellularProtein Kinase InhibitorsAntineoplastic AgentsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedRisk FactorsThyroxineThyrotropinAged, 80 and over

Stichwörter der Autor:innen

lenvatinib‐related hypothyroidismthyroid dysfunctiontyrosine kinase inhibitor

Substanzen

Phenylurea CompoundsQuinolineslenvatinibThyroxineProtein Kinase InhibitorsThyrotropinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.
  • Department of Pharmacy, Mie University Hospital, Mie, Japan.
  • Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Mie, Japan.

ORCID-Profile: Chihiro Shiraishi, Hideo Kato, Yuki Asai, Takuya Iwamoto

Zitieren

APA

Shiraishi, C., Kato, H., Asai, Y., & Iwamoto, T. (2026). Clinical Course and Risk Factors of Lenvatinib‐Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study. Cancer Reports. https://doi.org/10.1002/cnr2.70461

Vancouver

Shiraishi C, Kato H, Asai Y, Iwamoto T. Clinical Course and Risk Factors of Lenvatinib‐Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study. Cancer Reports. 2026. doi:10.1002/cnr2.70461

BibTeX
@article{Shiraishi2026,
  author = {Shiraishi, Chihiro and Kato, Hideo and Asai, Yuki and Iwamoto, Takuya},
  title = {Clinical Course and Risk Factors of Lenvatinib‐Related Hypothyroidism in Hepatocellular Carcinoma: A Retrospective Cohort Study},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70461}
}
Kostenlos starten →